8-K
filed August 15, 2023, 7:59 PM ET
ticker TRAW
CIK 0001130598
other
confidence high
sentiment neutral
materiality 0.15
Onconova stockholders elect eight directors, approve say-on-pay and auditor ratification at 2023 annual meeting
Traws Pharma, Inc.
- Elected all eight director nominees with majority 'For' votes; broker non-votes 3,588,614 each.
- Advisory say-on-pay approved: 4,959,016 For, 1,066,808 Against, 900,578 Abstain.
- Ratification of Ernst & Young as auditor approved: 9,271,526 For, 368,397 Against, 875,093 Abstain.
- Quorum achieved with 10,515,016 shares represented after prior adjournment on July 21, 2023.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Traws Pharma, Inc. shareholders approved To elect eight directors, each to hold office until the 2024 Annual Meeting of Stockholders and until his or her successor is elected and qualified. at the 2023-08-10 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-08-10
Exact text from the filing
Proposal 1. To elect eight directors, each to hold office until the 2024 Annual Meeting of Stockholders and until his or her successor is elected and qualified. Each nominee for director was elected by a vote of the stockholders as follows: Nominee For Withheld Broker Non-Votes James J. Marino 5,541,973 1,384,429 3,588,614 Steven M. Fruchtman 5,555,005 1,371,397 3,588,614 Peter Atadja 5,670,083 1,256,319 3,588,614 Trafford Clarke 5,541,659 1,384,743 3,588,614 Jerome E. Groopman 5,537,395 1,389,007 3,588,614 Viren Mehta 5,570,427 1,355,975 3,588,614 M. Teresa Shoemaker 5,592,043 1,334,359 3,588,614 Jack E. Stover 5,559,133 1,367,269 3,588,614
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Traws Pharma, Inc. shareholders approved To approve, on an advisory basis, the compensation of our named executive officers. at the 2023-08-10 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-08-10
Exact text from the filing
Proposal 2. To approve, on an advisory basis, the compensation of our named executive officers. The proposal was approved by a vote of the stockholders as follows: For Against Abstain Broker Non-Votes 4,959,016 1,066,808 900,578 3,588,614
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Traws Pharma, Inc. shareholders approved To consider and vote upon the ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-08-10 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-08-10
Exact text from the filing
Proposal 3. To consider and vote upon the ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. The proposal was approved by a vote of the stockholders as follows: For Against Abstain Broker Non-Votes 9,271,526 368,397 875,093 -
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.